Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05289167 · ClinicalTrials.gov registry record · Phase 1
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
A Phase 1 study of Graft-Versus-Host Disease, sponsored by Northwell Health.
- Active
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT05289167: Active Phase 1 study of Graft-Versus-Host Disease, sponsored by Northwell Health.
NCT05289167 is a Phase 1 study of Graft-Versus-Host Disease that is active but no longer recruiting, run by Northwell Health. The registered enrollment target is 74 participants, roughly in line with the 81-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05289167, a Phase 1 study of Graft-Versus-Host Disease, is active but no longer recruiting, sponsored by Northwell Health.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the criteria defined in our standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Subjects will receive a standard of care conditioning regimen. Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis.
Primary Outcome
Defined as grade 4 non-hematologic toxicity affecting the oral cavity, gastrointestinal tract, lung, heart, liver, kidney, bladder, or central nervous system.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Abatacept
- DRUG Bortezomib
Study Locations (1)
New York
- Northwell Health - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2022-03-13 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What the registry record for NCT05289167 still lists
NCT05289167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, roughly in line with the 81-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target.
The record links to 1 condition, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT05289167 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05289167 about?
NCT05289167 is a clinical study titled "Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)". This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the criteria defined in our standard operation procedures (SOPs),...
What is the current status of trial NCT05289167?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2022-03-13. Estimated completion is 2027-12.
What conditions does trial NCT05289167 study?
This clinical trial studies the following conditions: Graft-Versus-Host Disease.
What interventions are being tested in trial NCT05289167?
The interventions under investigation include: Cyclophosphamide (DRUG), Abatacept (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT05289167?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05289167 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft-Versus-Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05289167's enrollment target sits among peer trials
74 8th of 38 higher than 31 of 38 other Graft-Versus-Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graft-Versus-Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 1
-
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
RECRUITING · Phase 1
-
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
RECRUITING · Phase 1
-
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Optimizing PTCy Dose and Timing
ACTIVE NOT RECRUITING · Phase 1
-
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI